Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Established and emerging roles peptide YY (PYY) and exploitation in obesity–diabetes
Ryan A. Lafferty, Peter R. Flatt, Nigel Irwin
Current Opinion in Endocrinology Diabetes and Obesity (2020) Vol. 28, Iss. 2, pp. 253-261
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

A gut-derived hormone suppresses sugar appetite and regulates food choice in Drosophila
Alina Malita, Olga I. Kubrak, Takashi Koyama, et al.
Nature Metabolism (2022) Vol. 4, Iss. 11, pp. 1532-1550
Open Access | Times Cited: 59
The Specific Alteration of Gut Microbiota in Diabetic Kidney Diseases—A Systematic Review and Meta-Analysis
Yuwei Wang, Jin Zhao, Yunlong Qin, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 51
Physical Exercise and Diet: Regulation of Gut Microbiota to Prevent and Treat Metabolic Disorders to Maintain Health
Li Zhang, Yuan Liu, Wang Xinzhou, et al.
Nutrients (2023) Vol. 15, Iss. 6, pp. 1539-1539
Open Access | Times Cited: 22
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2024) Vol. 173, pp. 171149-171149
Open Access | Times Cited: 11
New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists
Ferenc Sztanek, László Imre Tóth, Attila Pető, et al.
Biomedicines (2024) Vol. 12, Iss. 6, pp. 1320-1320
Open Access | Times Cited: 10
Proglucagon-Derived Peptides as Therapeutics
Ryan A. Lafferty, Finbarr O’Harte, Nigel Irwin, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 49
Neuropeptide Y Peptide Family and Cancer: Antitumor Therapeutic Strategies
Manuel Lisardo Sánchez, Francisco D. Rodríguez, Rafael Coveñas
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 9962-9962
Open Access | Times Cited: 20
Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetes
Wuyun Zhu, Neil Tanday, Peter R. Flatt, et al.
Peptides (2022) Vol. 160, pp. 170923-170923
Open Access | Times Cited: 25
The role of gut–islet axis in pancreatic islet function and glucose homeostasis
Qi Chen, Yuanyuan Gao, Fangyu Li, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Islet effects of cholecystokinin and exploitation in diabetes
Neil Tanday, Nigel Irwin, Peter R. Flatt
Elsevier eBooks (2025), pp. 305-325
Closed Access
Deciphering the effect of soluble dietary fiber from broccoli stem and leaf on metabolic syndrome and its hypoglycemic mechanism in diabetes mellitus
Yanli Wang, Shi-Kun Suo, Yan Shang, et al.
Food Bioscience (2025), pp. 106546-106546
Closed Access
The potential role of lactulose pharmacotherapy in the treatment and prevention of diabetes
Natural Chu, J Ling, Jie He, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 21
Gut microbiota and its roles in the pathogenesis and therapy of endocrine system diseases
Zhuoxuan Wu, Erkang Tian, Yuyang Chen, et al.
Microbiological Research (2022) Vol. 268, pp. 127291-127291
Open Access | Times Cited: 19
Endogenous glucagon‐like peptide (GLP)‐1 as alternative for GLP‐1 receptor agonists: Could this work and how?
Mark M. Smits, Jens J. Holst
Diabetes/Metabolism Research and Reviews (2023) Vol. 39, Iss. 8
Open Access | Times Cited: 12
Microbiota dysbiosis caused by dietetic patterns as a promoter of Alzheimer's disease through metabolic syndrome mechanisms
Víctor Navalón-Monllor, Laura Soriano-Romaní, Mariana Silva, et al.
Food & Function (2023) Vol. 14, Iss. 16, pp. 7317-7334
Closed Access | Times Cited: 7
Beneficial metabolic effects of recurrent periods of beta‐cell rest and stimulation using stable neuropeptide Y1 and glucagon‐like peptide‐1 receptor agonists
Neil Tanday, Ryan A. Lafferty, Peter R. Flatt, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 12, pp. 2353-2363
Open Access | Times Cited: 11
Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes
Clifford J. Bailey, Peter R. Flatt
Peptides (2024) Vol. 174, pp. 171168-171168
Closed Access | Times Cited: 1
Novel enzyme‐resistant pancreatic polypeptide analogs evoke pancreatic beta‐cell rest, enhance islet cell turnover, and inhibit food intake in mice
Wuyun Zhu, Neil Tanday, Ryan A. Lafferty, et al.
BioFactors (2024)
Open Access | Times Cited: 1
Is polypharmacy the future for pharmacological management of obesity?
Ryan A. Lafferty, Peter R. Flatt, Nigel Irwin
Current Opinion in Endocrine and Metabolic Research (2022) Vol. 23, pp. 100322-100322
Open Access | Times Cited: 7
Amplifying the antidiabetic actions of glucagon‐like peptide‐1: Potential benefits of new adjunct therapies
Neil Tanday, Peter R. Flatt, Nigel Irwin
Diabetic Medicine (2021) Vol. 38, Iss. 12
Open Access | Times Cited: 9
Multiplexed Assay to Quantify the PP-Fold Family of Peptides in Human Plasma Using Microflow Liquid Chromatography–Tandem Mass Spectrometry
Gemma Reverter‐Branchat, Philippe J. Eugster, Christina Kuenzli, et al.
Clinical Chemistry (2021) Vol. 68, Iss. 4, pp. 584-594
Open Access | Times Cited: 9
Engineering a potent and long-acting GLP-1/Y2 receptor dual agonist as a multi-agonist therapy for diabetes and obesity
Jing Xu, Shuang Wang, Han Wu, et al.
Peptides (2023) Vol. 169, pp. 171073-171073
Closed Access | Times Cited: 3
Classical and non-classical islet peptides in the control of β-cell function
Dawood Khan, R. Charlotte Moffett, Peter R. Flatt, et al.
Peptides (2021) Vol. 150, pp. 170715-170715
Open Access | Times Cited: 7
Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats
Ananyaa Sridhar, Dawood Khan, Mahmoud Abdelaal, et al.
PLoS ONE (2022) Vol. 17, Iss. 9, pp. e0274788-e0274788
Open Access | Times Cited: 5
Dynamic in Situ Confinement Triggers Ligand-Free Neuropeptide Receptor Signaling
M. Florencia Sánchez, Marina S. Dietz, Ulrike Müller, et al.
Nano Letters (2022) Vol. 22, Iss. 20, pp. 8363-8371
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top